Table 2: Main characteristics of HCV infection in the 17 SCD patients with positive HCV serology.

Patient Age, gender Positive HCV RNA HCV genotype Mode of contamination Hb level (g/dL) ALT (IU/L) Prothrombin time (%) Liver fibrosis score** Treatment
1 51, M Y* 4 Transfusion 7 157 61 F4 None
2 43, M Y 4c Transfusion 6.9 19 7.9 F3 None
3 44,M N ND NA 7.2 30 81 ND None
4 60,M N la Transfusion 6.4 26 61 F4 sofosbuvir + daclatasvir
5 59, F N 4 Transfusion 9.0 12 95 F0 Peg IFN + ribavirin
6 30, M N ND Transfusion 9.9 31 62 ND NA
7 49, M N 1a Transfusion 8.7 17 89 ND Peg IFN + ribavirin + telaprevir
8 32, M Y* 2 Transfusion 11.1 27 92 F1 None
9 42, M N ND Transfusion 9.7 10 73 ND None
10 46, F Y ND Transfusion 10.2 19 85 F1 None
11 49, F Y ND Transfusion 9.0 43 NA ND None
12 34, F Y* 1b Transfusion 9.2 35 92 F3 None
13 35, M Y ND Transfusion 7.0 62 97 F0 None
14 43, F N ND Transfusion 9.4 22 90 F0 None
15 52, F Y* 1b Transfusion 8.1 21 92 F1 None
16 41, F N ND Transfusion 8.0 36 97 ND None
17 57, M Y* 4 Transfusion 8.0 28 79 F3 None

HCV = hepatitis C virus; M = male; F = female; Y = Yes; N = No; Y* = patients with HCV viremia > 800,000 IU/mL at the last screening; ND = not done; NA = not available; Hb = haemoglobin; ALT = alanine aminotransferase; **Metavir fibrosis score; Peg-IFN = pegylated interferon.